Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do cyclo-oxygenase 2 inhibitors increase the risk of cardiovascular events?

Nature Clinical Practice Oncology volume 2, pages 434–435 (2005)Cite this article

boxed-textSolomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hawk ET and Levin B (2005) Colorectal cancer prevention. J Clin Oncol 23: 378–391

    Article  Google Scholar 

  2. Bresalier RS et al. (2005) A randomized trial of rofecoxib to prevent colorectal adenomas: the APPROVe trial. Gastroenterology 128: A35

    Google Scholar 

  3. Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102

    Article  CAS  Google Scholar 

  4. Spektor G and Fuster V (2005) Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now? Nat Clin Pract Cardiovasc Med 2: 290–300

    Article  CAS  Google Scholar 

  5. Chan AT et al. (2004) A prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med 140: 157–166

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant in Medicine in the Gastrointestinal Unit at Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School, Boston, MA, USA

    Andrew T Chan

  2. the Director of the Dana-Farber/Harvard Cancer Center Gastrointestinal Malignancies Program and an Associate Professor of Medicine at Harvard Medical School, Boston, MA, USA

    Charles S Fuchs

Authors
  1. Andrew T Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles S Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew T Chan.

Ethics declarations

Competing interests

Charles S Fuchs receives research support from Pfizer, AstraZeneca, and Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, A., Fuchs, C. Do cyclo-oxygenase 2 inhibitors increase the risk of cardiovascular events?. Nat Rev Clin Oncol 2, 434–435 (2005). https://doi.org/10.1038/ncponc0291

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0291

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing